在长期幸存的小细胞肺癌复发患者中,第二次免疫治疗的持续反应

Natalie Shammas1, Sajjad Bhatti2

  • 1Internal Medicine, CHI Saint Vincent Health System, Little Rock, Arkansas, USA.

BMJ case reports
|August 25, 2025
PubMed
概括

在扩散性小细胞肺癌 (ES-SCLC) 患者中,长期存活是可能的. 停用维持免疫治疗后的复发可以通过第二次免疫治疗有效治疗,从而实现持久的缓解.

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K